+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Allergy Relieving Eye Drops Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4895985
  • Report
  • June 2020
  • Region: Global
  • 111 pages
  • Mordor Intelligence

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Santen Pharmaceutical Co
  • MORE
The rise in prevalence and incidence rates of eye-related disorders, increased geriatric population, and increasing research and development in eye allergy medication are expected to boost the allergy-relieving eye drops market during the forecast period.

Eye Allergy has been increasing in recent years. According to a report by BioMed Research International 2017, the overall prevalence of ocular allergy among school children in Shanghai, China is about 28%. Also, it has been observed that around 15% to 20%of the US population suffers from an ocular allergy. This high prevalence of ocular allergy has increased the demand for allergy eye drops and hence, this factor has acted as a driving factor helping this market grow. However, side effects from allergy relieving eye drops, including irritation, headache, and others, have been restraining the overall growth of this market.

Key Market Trends

Antihistamines are Expected to Register a High Growth Rate Over the Forecast Period

Antihistamines are found to block histamine release from histamine-1 receptors and are used to treat the symptoms of an allergic reaction such as edema (swelling), itch, inflammation (redness), and watery eyes. Eye edema is a very common occurrence that is primarily caused by unhealthy cornea prior to surgery.

Subsequently, any procedure within the eye (such as cataract, glaucoma, or retinal surgery) can cause the cornea to fail and develop edema. Therefore antihistamines effectively treat edema and the market is expected to increase over the forecast period.

North America is Expected to Dominate the Allergy Relieving Eye Drops Market

North America includes the United States (US), Canada, and Mexico. The United States and Canada have developed healthcare systems and also spend huge amounts in research and development fo the same. Therefore, as a result, most of the global treatments are available in this region.

According to a Yanqing Feng et al, published in BioMed Research International 2017, among the US households, 34% prevalence of Ocular Allergy symptoms were reported in children. This high prevalence has thus increased the demands for ocular allergy medications, which is helping the growth of the Allergy Relieving Eye Drops market in the US region. Moreover, North America is anticipated to be a highly attractive market for allergy-relieving eye drops, owing to the high cost of prescription drugs and a significant number of people in this region covered by medical insurance.

Competitive Landscape

The majority of the allergy relieving eye drops are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market growth.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Santen Pharmaceutical Co
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Incidence of Ocular Diseases
4.2.2 Increasing Research and Development in Eye Allergy Medication
4.3 Market Restraints
4.3.1 Side Effects from Eye Drops
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Antihistamines
5.1.2 Non-steroidal anti-Inflammatory Drugs
5.1.3 Vasoconstrictors
5.1.4 Others
5.2 By Type
5.2.1 Seasonal and Perennial Allergic Conjunctivitis
5.2.2 Vernal Keratoconjunctivitis
5.2.3 Atopic Keratoconjunctivitis
5.2.4 Giant Papillary Conjunctivitis
5.2.5 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc. (Allergan Plc)
6.1.2 Johnson & Johnson
6.1.3 Pfizer Inc.
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Novartis AG
6.1.6 Bausch Health Companies Inc
6.1.7 Regeneron Pharmaceuticals
6.1.8 Santen Pharmaceutical Co

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
  • AbbVie Inc. (Allergan Plc)
  • Johnson & Johnson
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Bausch Health Companies Inc
  • Regeneron Pharmaceuticals
  • Santen Pharmaceutical Co
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll